Home » Stocks » SBBP

Strongbridge Biopharma PLC (SBBP)

Stock Price: $3.41 USD 0.09 (2.71%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $3.30 -0.11 (-3.23%) Feb 24, 5:32 PM
Market Cap 234.34M
Revenue (ttm) 28.11M
Net Income (ttm) -42.11M
Shares Out 56.11M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $3.41
Previous Close $3.32
Change ($) 0.09
Change (%) 2.71%
Day's Open 3.41
Day's Range 3.33 - 3.55
Day's Volume 713,766
52-Week Range 1.50 - 4.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development a...

GlobeNewsWire - 1 month ago

~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase ove...

GlobeNewsWire - 3 months ago

~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing's Syndrome ~ ~ RECORLEV™ (levoketocon...

Seeking Alpha - 3 months ago

The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some p...

GlobeNewsWire - 3 months ago

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development an...

Seeking Alpha - 3 months ago

Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 11.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead fo...

GlobeNewsWire - 3 months ago

~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGI...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development a...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...

PRNewsWire - 5 months ago

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP).

Seeking Alpha - 5 months ago

After reporting positive Recorlev Phase 3 top line data, SBBP management demonstrated incredible confidence by guiding investors to expect $250MM-$350MM/year in peak Recorlev sales/year.

GlobeNewsWire - 5 months ago

~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndr...

GlobeNewsWire - 5 months ago

~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Res...

Seeking Alpha - 6 months ago

Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows. If the data does not look good, SBBP options are very limited.

Seeking Alpha - 6 months ago

Strongbridge Biopharma plc's (SBBP) CEO John Johnson on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 40.00% and 27.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 6 months ago

~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~

GlobeNewsWire - 6 months ago

DUBLIN, Ireland and TREVOSE, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...

Zacks Investment Research - 7 months ago

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

DUBLIN, Ireland and TREVOSE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...

GlobeNewsWire - 7 months ago

Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020 Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020

GlobeNewsWire - 9 months ago

DUBLIN, Ireland and TREVOSE, Pa., May 20, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development ...

Seeking Alpha - 9 months ago

Strongbridge Biopharma Attractive Valuation With Catalysts Approaching

GlobeNewsWire - 9 months ago

Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020 Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020

Seeking Alpha - 9 months ago

Strongbridge Biopharma plc (SBBP) Management on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 5.00% and 11.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 9 months ago

Shares of Strongbridge Biopharma (NASDAQ:SBBP) were flat in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 9 months ago

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 11 months ago

DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development ...

Seeking Alpha - 11 months ago

Strongbridge Biopharma plc (SBBP) Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 7.41% and 12.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and TREVOSE, Pa., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...

Seeking Alpha - 1 year ago

Strongbridge Biopharma: A Big Opportunity For Cushing's Syndrome Patients And For Investors

GlobeNewsWire - 1 year ago

~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2...

Seeking Alpha - 1 year ago

The fall in the stock price has created a compelling 'sum of the parts' valuation story and shares have stabilized recently.

GlobeNewsWire - 1 year ago

~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of ...

Seeking Alpha - 1 year ago

Strongbridge Biopharma plc (SBBP) Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...

Zacks Investment Research - 1 year ago

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and TREVOSE, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development...

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and TREVOSE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...

GlobeNewsWire - 1 year ago

~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities and Characteristic Signs and Sympto...

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and TREVOSE, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the developmen...

Seeking Alpha - 1 year ago

Strongbridge Biopharma's (SBBP) CEO Matthew Pauls on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Strongbridge Biopharma has a promising clinical pipeline for the metabolic disease Cushing’s syndrome.

Zacks Investment Research - 1 year ago

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 26.47% and -7.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for th...

Seeking Alpha - 1 year ago

Strongbridge Biopharma PLC (SBBP) CEO Matthew Pauls on Q1 2019 Results - Earnings Call Transcript

About SBBP

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotid... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2015
CEO
Matthew Pauls
Employees
71
Stock Exchange
NASDAQ
Ticker Symbol
SBBP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SBBP stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 134.60% from the latest price.

Price Target
$8.00
(134.60% upside)
Analyst Consensus: Strong Buy